<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Uterine adenomyosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Uterine adenomyosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Uterine adenomyosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth A Stewart, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Uterine adenomyosis is a disorder in which endometrial glands and stroma are present within the myometrium (uterine musculature), resulting in hypertrophy of the surrounding myometrium. Patients with symptomatic adenomyosis will often present with uterine enlargement, abnormal uterine bleeding (AUB), and painful menses. Adenomyosis may also coexist with uterine leiomyoma and/or endometriosis. </p><p>Historically the diagnosis of adenomyosis was made retrospectively and based solely on histologic assessment of hysterectomy specimens. However, the diagnosis is now made by imaging-based criteria using transvaginal ultrasonography (TVUS) and/or magnetic resonance imaging (MRI) which has resulted in a greater understanding of the disease, its prevalence, effect on younger patients and patients with reproductive dysfunction, and treatment options.</p><p>The diagnosis and management of uterine adenomyosis will be reviewed here. Other topics related to uterine pathology and AUB are presented separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5486.html" rel="external">"Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7384.html" rel="external">"Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact"</a>.)</p><p></p><p class="headingAnchor" id="H1001786944"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of adenomyosis is not known. Four theories suggest that adenomyosis occurs from [<a href="#rid1">1-5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Endomyometrial invagination of the endometrium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>De novo from müllerian remnants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Microtrauma of the endometrial/myometrial interface (ie, junction zone [JZ]).</p><p></p><p>Disruption of the JZ may result in ultrastructural changes and differential growth factor (GF) expression that may result in migration of the endometrial cells into the myometrium [<a href="#rid6">6-10</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Establishment of lesions from retrograde menstruation of endometrial cells.</p><p></p><p>The lack of basement membrane between the endometrium and myometrium likely influences these processes. </p><p>Estrogen and progesterone also contribute to adenomyosis pathophysiology, as in other gynecologic disorders; both estrogen and progesterone receptors appear to be upregulated in patients with adenomyosis. Studies suggest that estrogen is produced in, and appears to be a mitogen for, adenomyotic tissue [<a href="#rid11">11</a>]. In a murine model of adenomyosis, early exposure to estrogen modulators (in this experiment, <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>) led to an increased risk of adenomyosis and abnormal myometrium, which also supports the invagination hypothesis [<a href="#rid12">12</a>]. In humans treated with tamoxifen (a selective estrogen receptor modulator [SERM] used in the treatment and prevention of some breast cancers), histopathologic uterine changes consistent with adenomyosis have been reported [<a href="#rid13">13</a>]. Similarly, treatments that inhibit estrogen production (eg, gonadotropin-releasing hormone [GnRH] agonists and antagonists, <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a>) normalize aromatase expression in the endometrium of patients with adenomyosis [<a href="#rid14">14,15</a>]. (See <a class="local">'Alternative hormone strategies'</a> below.) </p><p>Other animal models suggest that pituitary protein hormones (eg, prolactin, follicle-stimulating hormone, oxytocin) may also have roles in the pathogenesis adenomyosis [<a href="#rid2">2,11,16-23</a>]. This hypothesis is strengthened by research showing that, in patients with adenomyosis, dopamine agonists (eg, <a class="drug drug_general" data-topicid="9164" href="/z/d/drug information/9164.html" rel="external">bromocriptine</a>; used for treatment of hyperprolactinemia) result in improvement in menstrual bleeding, pain, and quality of life [<a href="#rid24">24,25</a>]. However, this association may be a result of improved chronic pain or depression, rather than adenomyosis itself. Furthermore, the steroid and pituitary hormone pathways may be functionally linked. Progesterone appears to upregulate prolactin in adenomyosis cells, as it does in the endometrium [<a href="#rid11">11,23</a>]. Additionally, in normal myometrium and leiomyomas, prolactin can act as a smooth muscle cell mitogen [<a href="#rid16">16</a>].</p><p>Expression of other key molecules (eg, BCL2 gene expression, superoxide dismutase, granulocyte macrophage colony-stimulating factor, <em>KRAS</em>) in adenomyotic cells may also differ from eutopic endometrial glands [<a href="#rid26">26-31</a>]. Stem cells and immune and inflammatory mediators also appear to play a role [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H17829601"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The epidemiology of adenomyosis is uncertain because data regarding adenomyosis has often relied on the assessment of the uterus following hysterectomy. Thus, what is reported here as the epidemiology of adenomyosis may, in fact, be reflecting the epidemiology of hysterectomy:</p><p class="bulletIndent1"><span class="glyph">●</span>Studies report that adenomyosis is present in a wide range (eg, 9 to 62 percent) of individuals undergoing hysterectomy [<a href="#rid10">10</a>]. Variability is present not only with differing populations and reasons for hysterectomy (eg, adenomyosis is more common in patients with leiomyomas), but different diagnostic criteria used, and number of histologic sections examined. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one retrospective study including 137 patients who underwent hysterectomy (at a mean age of 49 years) and in whom pathology reports were available, almost half (48 percent) had histologic-confirmed adenomyosis [<a href="#rid32">32</a>]. The authors of this study argued that adenomyosis is a normal variant and not a true disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adenomyosis was previously described as a disease that developed between the ages of 40 and 50 years, which is also the age at which most hysterectomies are performed [<a href="#rid10">10</a>]. However, studies utilizing imaging diagnosis of adenomyosis suggest that adenomyosis can frequently be detected at younger ages (prevalence rates of 20 to 35 percent) [<a href="#rid33">33-35</a>], with one study reporting a mean age of 26 years for patients with an imaging diagnosis of adenomyosis [<a href="#rid35">35</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adenomyosis appears to be more common in parous than nulliparous patients [<a href="#rid32">32,36,37</a>]. However, this relationship is likely biased since nulliparous compared with parous patients are less likely to undergo hysterectomy. Interestingly, a greater number of pregnancies is not associated with a higher risk of the disease [<a href="#rid38">38</a>]. Other reproductive risk factors may include earlier age at menarche (≤10 years), shorter menstrual cycle duration (≤25 days), and use of menopausal hormone therapy [<a href="#rid10">10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adenomyosis may occur more commonly in patients with prior uterine surgery [<a href="#rid24">24,39</a>]. However, patients with prior uterine surgery may also be more likely to undergo hysterectomy. </p><p></p><p class="headingAnchor" id="H2423291910"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H6"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Presenting symptoms of adenomyosis include heavy menstrual bleeding, painful menses, and chronic pelvic pain. Some patients may present with infertility [<a href="#rid40">40</a>]. Historically, it was thought that approximately one-third of patients were asymptomatic [<a href="#rid36">36</a>]; however, this is likely an overestimate, and more recent studies report much lower rates (4.5 percent) of asymptomatic patients [<a href="#rid41">41</a>]. </p><p>Heavy menstrual bleeding, also referred to as abnormal uterine bleeding-adenomyosis (AUB-A) in the International Federation of Gynecology and Obstetrics (FIGO), or PALM-COEIN, classification system  (<a class="graphic graphic_figure graphicRef90483" href="/z/d/graphic/90483.html" rel="external">figure 1</a>), occurs in approximately 50 to 60 percent of patients with adenomyosis [<a href="#rid36">36,41</a>]. AUB may be related to the increased surface of the enlarged uterus, an overexpression of inflammatory mediators in the adenomyotic tissue, or contractile dysfunction of the uterine smooth muscle as a result of the ectopic endometrium [<a href="#rid42">42,43</a>].</p><p>Painful menses occurs in approximately 25 to 80 percent of patients, depending on the population studied [<a href="#rid36">36,41</a>]. Pain may be due to bleeding and swelling of endometrial islands confined by myometrium. </p><p class="headingAnchor" id="H3046699291"><span class="h2">Associated conditions</span><span class="headingEndMark"> — </span>Adenomyosis often coexists with other uterine diseases, particularly uterine leiomyomas and endometriosis, which can obscure the diagnosis of adenomyosis and make delineation of a symptom profile specific to adenomyosis difficult. </p><p class="headingAnchor" id="H2781756795"><span class="h3">Endometriosis</span><span class="headingEndMark"> — </span>While both adenomyosis and endometriosis represent disorders of ectopic endometrium and can be a cause of pelvic pain, the two diseases are not thought to be otherwise related. Thus, in our practice, we avoid using the older term for adenomyosis, "endometriosis interna." (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/7384.html" rel="external">"Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact"</a>.)</p><p>Adenomyosis and endometriosis, however, coexist and in patients with persistence of pelvic pain following optimal endometriosis surgical therapy, the presence of adenomyosis should be more strongly considered [<a href="#rid44">44,45</a>]. In one prospective study including 227 patients with infertility, patients with endometriosis (70 percent of patients) versus without endometriosis had higher rates of concurrent adenomyosis (79 versus 28 percent); adenomyosis was diagnosed by MRI [<a href="#rid46">46</a>]. The prevalence was highest (90 percent) in patients &lt;36 years with endometriosis and a partner with a normal sperm count.</p><p>Patient characteristics may differ between groups. In a longitudinal study recruiting females starting at age 22, patients with adenomyosis compared with endometriosis had increased parity, earlier menarche, and shorter menstrual cycles [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H3115770991"><span class="h3">Leiomyoma</span><span class="headingEndMark"> — </span>Adenomyosis also often coexists with leiomyoma. In the longitudinal study discussed above including patients with adenomyosis or endometriosis, over one-half of the patients in both groups had concomitant leiomyomas [<a href="#rid37">37</a>].</p><p>As with endometriosis, patient characteristics may differ between those with adenomyosis or leiomyomas. In a case-control study comparing patients undergoing hysterectomy with a pathologic diagnosis of adenomyosis alone (cases) versus leiomyomas alone (controls), those with adenomyosis were younger and more likely to have dysmenorrhea, pelvic pain, depression, and a history of prior uterine surgery [<a href="#rid24">24</a>]. In a multivariate analysis confined to patients with uteri weighing more than 150 grams, patients with adenomyosis were more likely to have depression and endometriosis compared with patients with only fibroids [<a href="#rid24">24</a>]. Similarly, while increased parity may be associated with increased rates of adenomyosis (see <a class="local">'Epidemiology'</a> above), the opposite is seen in patients with leiomyomas, in whom parity is associated with a decreased risk of disease. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/5486.html" rel="external">"Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history", section on 'Parity'</a>.)</p><p>There is also evidence that adenomyosis and leiomyomas share elements of pathogenesis such as growth factor dysregulation and abnormalities of angiogenesis [<a href="#rid29">29,47-52</a>]. Thus, some therapies that are used for the treatment of leiomyomas may also be used for treatment of those with adenomyosis. (See <a class="local">'Management of symptomatic patients'</a> below.) </p><p class="headingAnchor" id="H2350061149"><span class="h3">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse pregnancy outcomes</strong> – Adenomyosis may be associated with poor pregnancy outcomes, including miscarriage, preterm birth, and small-for-gestational-age (SGA) infants [<a href="#rid53">53-55</a>]. </p><p></p><p class="bulletIndent1">In a meta-analysis of four studies and over 1100 patients, those with adenomyosis (13 percent) versus without adenomyosis had higher rates of preterm birth (odds ratio [OR] 3.09, 95% CI 1.88-5.09) and SGA (OR 3.23, 95% CI 1.71-6.09) [<a href="#rid54">54</a>]. A subsequent meta-analysis also showed an association between adenomyosis and miscarriage (OR 3.49, CI 1.41-8.65; six patients) [<a href="#rid55">55</a>]. These associations may be related to confounders or misdiagnosis of adenomyosis, and further studies are needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infertility</strong> – Adenomyosis may be associated with infertility; however, there are many confounders with such an association (eg, hysterectomy was previously required for diagnosis, endometriosis commonly coexists) and most of the evidence comes from small case series [<a href="#rid56">56,57</a>]. </p><p></p><p class="bulletIndent1">In a meta-analysis of 11 cohort studies including 2054 patients undergoing in vitro fertilization (IVF), those with adenomyosis (25 percent) versus without adenomyosis had lower rates of implantation, clinical pregnancy per cycle, clinical pregnancy per embryo transfer, ongoing pregnancy, and live birth [<a href="#rid58">58</a>]. These findings are supported by an earlier animal study which showed that baboons with infertility had a 20-fold increase of histologic adenomyosis even when concomitant endometriosis was excluded [<a href="#rid59">59</a>]. </p><p></p><p class="bulletIndent1">The type of adenomyosis (ie, focal or diffuse) may also impact fertility (see <a class="local">'Histopathology'</a> below). In a cross-sectional study including almost 248 patients with adenomyosis (mean age 32 years), the prevalence of infertility was 30 percent; after controlling for age and coexisting leiomyoma or endometriosis, focal adenomyosis was independently associated with primary infertility (adjusted OR 1.9; 95% CI 1.1-3.3) [<a href="#rid60">60</a>]. Diffuse adenomyosis did not appear to be associated with infertility. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer</strong> – Adenomyosis may be associated with an increase in some cancers.</p><p></p><p class="bulletIndent1">In a retrospective study including over 760 patients with adenomyosis, patients with adenomyosis compared with controls had higher rates of ovarian cancer (adjusted hazard ratio [aHR] 5.5, 1.95-15.5), endometrial cancer (aHR 5.13, 1.36-19.4) and colorectal cancer (aHR 13.04, 2.21-77.04) [<a href="#rid61">61</a>]. Similarly, in a subsequent population-based study including over 12,000 females with adenomyosis and age-matched controls, adenomyosis was associated with an increased risk of endometrial cancer (HR 2.2, 95% CI 1.5-3.2) and thyroid cancer (HR 1.7, 95% CI 1.3-2.2) [<a href="#rid62">62</a>]. Both studies relied on large administrative databases and did not control for clinical risk factors such as parity, anovulatory bleeding, and colorectal screening practices. Confirmation of these findings in appropriately controlled studies would likely impact screening for these diseases.</p><p></p><p class="headingAnchor" id="H3753829039"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Patients with suspected adenomyosis are evaluated with a medical history, pelvic examination, and pelvic imaging. Laboratory testing is not needed to diagnose adenomyosis.</p><p class="headingAnchor" id="H114038503"><span class="h2">History</span><span class="headingEndMark"> — </span>A medical history is taken, including a full obstetric and gynecologic history. Patients should be asked about other conditions or medications that can cause abnormal uterine bleeding (AUB) or pelvic pain. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis", section on 'History'</a>.)</p><p class="headingAnchor" id="H4204643159"><span class="h2">Pelvic examination</span><span class="headingEndMark"> — </span>A pelvic examination is performed. Typical findings of adenomyosis include a mobile uterus that is diffusely enlarged (often referred to as "globular"), soft (often referred to as "boggy"), and tender. The uterus rarely exceeds the size of a pregnant uterus at 12 weeks of gestation [<a href="#rid63">63</a>]. While some patients have a symmetrical uterus, others have irregular masses (termed adenomyomas), which clinically resemble leiomyomas. </p><p>Adenomyosis does not result in a fixed uterus, but this may occur with endometriosis, which often coexists with adenomyosis. (See <a class="local">'Endometriosis'</a> above.)</p><p class="headingAnchor" id="H3149457402"><span class="h2">Imaging</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modality</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transvaginal ultrasound and magnetic resonance imaging </strong>– Transvaginal ultrasound (TVUS) is the first-line imaging study for evaluation of an enlarged uterus, pelvic pain, and/or abnormal bleeding. The images should be reviewed by a radiologist or gynecologist experienced in evaluating adenomyosis. While there are clear consensus definitions for the diagnosis of adenomyosis with ultrasound [<a href="#rid64">64</a>], not all individuals performing or reading ultrasound systematically search for evidence of the disease.</p><p></p><p class="bulletIndent2">MRI is typically reserved for patients in whom it is important to distinguish between diffuse and focal adenomyosis, focal adenomyosis and leiomyomas, and/or to help with treatment (eg, surgical, interventional) planning [<a href="#rid65">65</a>]. (See <a class="local">'Uterus-sparing resection'</a> below.)</p><p></p><p class="bulletIndent2">Both TVUS and MRI have a high sensitivity and specificity for diagnosing adenomyosis. In a meta-analysis including over 3300 patients with adenomyosis confirmed on hysterectomy specimen, TVUS had a sensitivity and specificity for diagnosing adenomyosis of 81 and 87 percent, respectively [<a href="#rid66">66</a>]. The sensitivity and specificity with MRI were 71 and 91 percent, respectively.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hysterosalpingogram </strong>– Hysterosalpingogram (HSG), primarily used to determine tubal patency in patients with infertility, may show multiple small outpourings of endometrium extending into the myometrium. (See  <a class="medical medical_review" href="/z/d/html/3262.html" rel="external">"Hysterosalpingography", section on 'Uterine contour abnormalities'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Computed tomography (CT) has no role in the assessment of adenomyosis [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Findings</strong> – Findings of adenomyosis on TVUS or MRI vary and include  (<a class="graphic graphic_figure graphicRef141558" href="/z/d/graphic/141558.html" rel="external">figure 2</a>) [<a href="#rid64">64</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An enlarged uterus.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Asymmetric thickening of the myometrium (with the posterior myometrial typically thicker)  (<a class="graphic graphic_diagnosticimage graphicRef119464" href="/z/d/graphic/119464.html" rel="external">image 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Myometrial cysts  (<a class="graphic graphic_diagnosticimage graphicRef119463" href="/z/d/graphic/119463.html" rel="external">image 2</a>). Typically, these cysts are small (eg, 2 to 5 mm), and for histologic diagnosis, the cysts must be separated from the endometrium by at least 2 low-power fields. (See <a class="local">'Histopathology'</a> below.)</p><p></p><p class="bulletIndent2">In the past, the term "cystic" was used to describe adenomyomas ≥1 cm in diameter on imaging studies. The entity "juvenile cystic adenomyoma" has been used to describe a syndrome in which females 30 years or younger with severe dysmenorrhea have myometrial cysts ≥1 cm [<a href="#rid68">68</a>]. However, cystic adenomyosis has been reported in females of a variety of reproductive ages [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyperechoic islands in the myometrium.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Linear striations radiating out from the endometrium  (<a class="graphic graphic_diagnosticimage graphicRef119462" href="/z/d/graphic/119462.html" rel="external">image 3</a>). This can also be described as fan-shaped shadowing and appears as alternating bands of shadowing and hyperechogenicity on ultrasound. These are thought to be caused by the small cysts in the myometrium allowing for increased through transmission and shadowing caused by the surrounding compact myometrium.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased lesional vascularity in adenomyomas. By contrast, peripheral vascularity is seen in leiomyomas.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased myometrial heterogeneity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Thickening, interruption, or irregularities of the junctional zone (JZ) on MRI (endomyometrial border). Some quantitation of the thickening of the JZ is possible (termed "junctional zone hyperplasia"), with &gt;12 mm generally considered diagnostic of the disease [<a href="#rid70">70</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Echogenic subendometrial lines or buds extending from the JZ.</p><p></p><p class="bulletIndent1">Features of adenomyosis can also change with the menstrual cycle. For example, cysts may become larger and echogenic masses within the myometrium may change in echogenicity during the menstrual cycle.</p><p></p><p class="headingAnchor" id="H1931384350"><span class="h2">Limited role of other tests</span><span class="headingEndMark"> — </span>There are no laboratory tests that diagnose adenomyosis [<a href="#rid71">71</a>]. The following tests may be utilized in addition to imaging for selected patients to evaluate other conditions:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urine or serum hCG</strong> – A urine or serum human chorionic gonadotropin (hCG) should be measured to exclude pregnancy in reproductive-age patients with uterine enlargement, AUB, or pelvic pain. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoglobin or hematocrit</strong> – A hemoglobin/hematocrit may be ordered for patients with AUB or when anemia is suspected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chlamydia and/or gonorrhea</strong> – If pelvic pain is present, tests to exclude infection may be sent, if appropriate. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endometrial biopsy</strong> – Endometrial biopsy is not informative in the diagnosis of adenomyosis since it is a myometrial disease. However, it is often required in patients with adenomyosis since they have AUB, and endometrial hyperplasia or carcinoma must be excluded. In addition, thickening of the junctional zone on ultrasound can sometimes be misinterpreted as endometrial thickening, which may lead to additional endometrial evaluation (eg, endometrial biopsy, dilation and curettage with hysteroscopy) in some patients. (See  <a class="medical medical_review" href="/z/d/html/3232.html" rel="external">"Overview of the evaluation of the endometrium for malignant or premalignant disease", section on 'Transvaginal ultrasound'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Needle biopsy</strong> – Needle biopsy of the myometrium is not common practice and is reserved for clinical situations in which a malignancy needs to be excluded. Sensitivity of needle biopsy depends on several factors, including the extent of disease, number of biopsy specimens obtained, sampling site, needle gauge, and operator experience [<a href="#rid63">63</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>A definitive diagnosis of adenomyosis is made based on the finding of endometrial tissue within the myometrium during pathology evaluation of the uterus after hysterectomy. (See <a class="local">'Histopathology'</a> below.)</p><p>A presumptive diagnosis of adenomyosis can be made in patients with characteristic clinical manifestations (eg, heavy menstrual bleeding and dysmenorrhea in a patient with an enlarged uterus) and imaging findings consistent with adenomyosis. (See <a class="local">'Clinical presentation'</a> above and <a class="local">'Imaging'</a> above.)</p><p class="headingAnchor" id="H3497135036"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>There are three forms of adenomyosis: diffuse, focal and junctional zone disease.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diffuse adenomyosis</strong> – On gross inspection, the uterus with diffuse adenomyosis is uniformly enlarged and boggy. The average uterine weight is usually between 80 and 200 grams, unless coexisting leiomyomas are present. </p><p></p><p class="bulletIndent1">Upon sectioning the uterus, the myometrial wall appears thickened and small hemorrhagic or chocolate-colored areas (representing islands of endometrial bleeding) without well-demarcated borders are dispersed throughout the myometrium  (<a class="graphic graphic_picture graphicRef141619" href="/z/d/graphic/141619.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Focal adenomyosis (also called adenomyoma)</strong> – On gross inspection, focal adenomyosis can resemble a leiomyoma but without its characteristic pseudocapsule which allows for easy enucleation during surgical resection. </p><p></p><p class="bulletIndent1">Upon sectioning the uterus, circumscribed, nodular aggregates of hemorrhagic or chocolate-colored areas are visualized in only one part of the myometrium. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Junctional zone disease </strong>– The junctional zone (JZ) is the border between the endometrium and myometrium; the presence of endometrial tissue within the myometrium at a distance of at least two low-power fields (though proposed cut-off values are variable) from the JZ is pathognomonic of adenomyosis  (<a class="graphic graphic_picture graphicRef141619" href="/z/d/graphic/141619.html" rel="external">picture 1</a>) [<a href="#rid72">72</a>]. The distance requirement is to preclude mistaking the normal endometrium between muscle fibers at the mucosa for adenomyosis when the specimen is transected for slide preparation. The ectopic endometrium usually has an immature proliferative pattern.</p><p></p><p class="bulletIndent1">While thickening, discontinuity, and interruption of the JZ can be clearly visible on MRI (see <a class="local">'Imaging'</a> above), its use as a histologic marker of adenomyosis is limited. In addition, a prior history of endometrial ablation can confound the diagnosis of adenomyosis as the procedure distorts or destroys the JZ.</p><p></p><p class="headingAnchor" id="H8"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of adenomyosis includes other conditions that cause uterine enlargement, abnormal uterine bleeding (AUB)  (<a class="graphic graphic_table graphicRef74527" href="/z/d/graphic/74527.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef61684" href="/z/d/graphic/61684.html" rel="external">table 2</a>), and/or dysmenorrhea  (<a class="graphic graphic_table graphicRef78903" href="/z/d/graphic/78903.html" rel="external">table 3</a>). Negative pregnancy testing excludes conditions associated with bleeding during pregnancy. </p><p>Most commonly, adenomyosis must be differentiated from uterine leiomyomas and endometriosis.</p><p class="bulletIndent1"><span class="glyph">●</span>Uterine leiomyomas may cause uterine enlargement and heavy menstrual bleeding. While leiomyomas tend to cause noncyclic pelvic pain or pressure, they may also be associated with dysmenorrhea. Pelvic imaging can usually differentiate the two conditions, but fibroids may also coexist with adenomyosis, and if a patient has both, it can be difficult to know which is the cause of the patient's symptoms. (See <a class="local">'Leiomyoma'</a> above and  <a class="medical medical_review" href="/z/d/html/5486.html" rel="external">"Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endometriosis classically present with dysmenorrhea, dyspareunia, and infertility. Endometriosis usually requires surgery for diagnosis, but some patients may have characteristic findings (eg, ovarian endometrioma, extrauterine endometrial implants) on imaging. Patients with persistent pain following adequate treatment for endometriosis may have adenomyosis as an underlying diagnosis [<a href="#rid45">45</a>]. (See <a class="local">'Endometriosis'</a> above and  <a class="medical medical_review" href="/z/d/html/7384.html" rel="external">"Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact"</a> and  <a class="medical medical_review" href="/z/d/html/134970.html" rel="external">"Endometriosis: Clinical features, evaluation, and diagnosis", section on 'Findings'</a>.)</p><p></p><p>Less common conditions that need to be differentiated from adenomyosis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic endometritis can cause AUB and dysmenorrhea. While the uterus is often tender, it is typically normal in size (unless coexisting adenomyosis or leiomyomas are present). An endometrial biopsy demonstrating plasma cells in the endometrial stroma is diagnostic of chronic endometritis. (See  <a class="medical medical_review" href="/z/d/html/5462.html" rel="external">"Endometritis unrelated to pregnancy", section on 'Chronic endometritis'</a> and  <a class="medical medical_review" href="/z/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pelvic inflammatory disease (PID) may present with acute or subacute pelvic pain. Cervical motion, uterine, and adnexal tenderness on bimanual pelvic examination are the defining characteristics of acute symptomatic PID, and purulent endocervical discharge and/or vaginal discharge is also common. While AUB can occur, it is less common than with adenomyosis. (See  <a class="medical medical_review" href="/z/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with AUB should also be evaluated for endometrial carcinoma, as appropriate. (See  <a class="medical medical_review" href="/z/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/16924.html" rel="external">"Endometrial carcinoma: Clinical features, diagnosis, prognosis, and screening"</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h1">MANAGEMENT OF SYMPTOMATIC PATIENTS</span><span class="headingEndMark"> — </span>Management of patients with symptomatic adenomyosis is described here  (<a class="graphic graphic_algorithm graphicRef141667" href="/z/d/graphic/141667.html" rel="external">algorithm 1</a>). Patients with adenomyosis but no symptoms do not require treatment. </p><p class="headingAnchor" id="H1171460406"><span class="h2">First line therapies</span></p><p class="headingAnchor" id="H1258566710"><span class="h3">NSAIDs</span><span class="headingEndMark"> — </span>If not already initiated, first line therapy includes nonsteroidal anti-inflammatory drugs (NSAIDs; <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>, <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a>, <a class="drug drug_general" data-topicid="9601" href="/z/d/drug information/9601.html" rel="external">mefenamic acid</a>), which are effective for the treatment of heavy menstrual bleeding and dysmenorrhea. These are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management", section on 'Nonhormonal therapies'</a> and  <a class="medical medical_review" href="/z/d/html/5414.html" rel="external">"Dysmenorrhea in adult females: Treatment", section on 'First-tier'</a>.)</p><p class="headingAnchor" id="H1242069163"><span class="h3">52 mg levonorgestrel IUD</span><span class="headingEndMark"> — </span>In our practice, first line therapy also includes the 52 mg levonorgestrel-releasing intrauterine device (LNG 52), given its direct action on the uterus, low systemic levels of steroid hormones, and long-acting user-independent administration. </p><p>Observational studies suggest that the LNG 52 improves both adenomyosis-associated heavy menstrual bleeding and dysmenorrhea [<a href="#rid73">73-76</a>]. In one observational study including 29 patients with MRI-diagnosed adenomyosis, treatment with the LNG 52 for six months was associated with a 24 percent reduction in the thickness of the junctional zone on MRI as well as a reduction in pain and abnormal bleeding in most patients [<a href="#rid76">76</a>]. In a subsequent observational study including 94 patients with transvaginal ultrasound-diagnosed adenomyosis, treatment with the LNG 52 was associated with a reduction in dysmenorrhea and uterine volume during the 29 month (mean) follow-up period; IUD expulsion (16 percent) or premature removal (18 percent) occurred in over one-third of patients [<a href="#rid75">75</a>]. </p><p>While other <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a> (ie, LNG 19.5, LNG 13.5) are available, the data on adenomyosis treatment were generated based on the 52 mg system. Thus, for the purposes of adenomyosis treatment, this formulation is preferred. (See  <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Devices and characteristics'</a>.)</p><p class="headingAnchor" id="H2518419982"><span class="h2">Alternative hormone strategies</span><span class="headingEndMark"> — </span>For patients who prefer not to, or cannot use, the LNG 52, other hormonal strategies may be used; data on efficacy are limited:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral contraceptive pills</strong> – While data on the efficacy of estrogen-progestin contraceptives for the treatment of adenomyosis are limited, these contraceptives are effective as primary treatments for heavy menstrual bleeding and dysmenorrhea; thus, a trial of estrogen-progestin contraceptives is reasonable. </p><p></p><p class="bulletIndent1">In a randomized trial including 57 patients with ultrasound-diagnosed adenomyosis in whom six-month follow-up data was available, treatment with oral contraceptives or LNG 52 IUD both reduced reducing pain and bleeding, but larger reductions were demonstrated in the LNG 52 IUD group [<a href="#rid77">77</a>]. Other contraceptive pill options, including progesterone only pills (eg, <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate) and <a class="drug drug_general" data-topicid="17068" href="/z/d/drug information/17068.html" rel="external">dienogest</a> (available outside the United States as a single agent), have also been described [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GnRH agonists and antagonists</strong> – Gonadotropin-releasing hormone (GnRH) analog combinations (<a class="drug drug_general" data-topicid="118522" href="/z/d/drug information/118522.html" rel="external">elagolix</a> plus estradiol and <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a>, relugolix plus estradiol and norethindrone), approved for the treatment of heavy menstrual bleeding in patients with uterine fibroids, may also be used for patients with concomitant adenomyosis [<a href="#rid79">79-84</a>]. However, the use of these agents with isolated adenomyosis has not been studied.</p><p></p><p class="bulletIndent1">In an analysis of two identical phase III trials including 126 patients with fibroid-related heavy menstrual bleeding and concurrent adenomyosis diagnosed on imaging, more patients treated with <a class="drug drug_general" data-topicid="118522" href="/z/d/drug information/118522.html" rel="external">elagolix</a> plus hormonal add-back therapy (elagolix 300 mg twice a day with daily estradiol 1 mg and <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate 0.5 mg) compared with placebo met the primary endpoint of menstrual blood loss of &lt;80 mL during the final month of treatment and at least a 50 percent reduction in menstrual blood loss from baseline to the final month (range 77 versus 12 percent) [<a href="#rid85">85</a>]. Side effects were modest, including hot flushes (18 percent), nausea (11 percent), and night sweats (8 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Use of other hormonal options including aromatase inhibitors, oxytocin antagonists, and progesterone receptor modulators have been described [<a href="#rid78">78,86</a>], but data are limited and we do not use these routinely in our practice. </p><p></p><p class="bulletIndent1">In one randomized trial including 134 premenopausal patients with MRI- or ultrasound-diagnosed adenomyosis, those receiving <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">mifepristone</a> (10 mg orally daily) compared with placebo had a greater improvement of dysmenorrhea (92 versus 23 percent), blood loss (mean increase in hemoglobin: 2.1 versus 0.48 g/dL), and uterine volume (mean change: -29.3 versus -18.4 cm<sup>3</sup>) after twelve weeks of treatment [<a href="#rid86">86</a>]. Further studies are needed to determine the long-term efficacy of mifepristone in such patients. </p><p></p><p>When hormonal medications are discontinued (eg, when a patient wants to conceive) recurrence of symptoms and enlargement of the uterus in those with treatment associated volume reduction are usually documented within six months.</p><p class="headingAnchor" id="H3323056750"><span class="h2">Later line: Surgical procedures</span></p><p class="headingAnchor" id="H1616184979"><span class="h3">Patients who have completed childbearing</span></p><p class="headingAnchor" id="H645247194"><span class="h4">Hysterectomy</span><span class="headingEndMark"> — </span>For patients who have completed childbearing and in whom first-line therapies were ineffective or contraindicated, hysterectomy is the definitive treatment option. Hysterectomy is also the only way to remove diffuse adenomyosis and is generally preferred to the removal of adenomyomas with uterine conservation, except where future pregnancy is desired. (See <a class="local">'Patients who desire future childbearing'</a> below.)</p><p>However, patients with adenomyosis in whom pain is the primary or sole symptom should be carefully counseled that they may continue to have pain following hysterectomy as neural pathways of pain may still be active.</p><p>The procedure for hysterectomy is the same as for other benign indications and may be performed via laparotomy, transvaginal, laparoscopy, or robotic surgery. Since disease is confined to the uterine corpus, the ovaries may be conserved. (See  <a class="medical medical_review" href="/z/d/html/3272.html" rel="external">"Hysterectomy (benign indications): Selection of surgical route"</a> and  <a class="medical medical_review" href="/z/d/html/3311.html" rel="external">"Hysterectomy: Abdominal (open) route"</a> and  <a class="medical medical_review" href="/z/d/html/3286.html" rel="external">"Hysterectomy: Laparoscopic"</a> and  <a class="medical medical_review" href="/z/d/html/3308.html" rel="external">"Hysterectomy: Vaginal"</a>.) </p><p class="headingAnchor" id="H2570603116"><span class="h4">Uterine artery embolization, as an alternative</span><span class="headingEndMark"> — </span>For patients who have failed hormonal treatment and decline, or have contraindications to, a hysterectomy, uterine artery embolization (UAE) may be used to reduce symptoms related to adenomyosis  (<a class="graphic graphic_diagnosticimage graphicRef53441" href="/z/d/graphic/53441.html" rel="external">image 4</a>). UAE is not intended for use in patients who desire to optimize future childbearing as adverse pregnancy outcomes can occur. (See  <a class="medical medical_review" href="/z/d/html/3299.html" rel="external">"Uterine fibroids (leiomyomas): Treatment with uterine artery embolization", section on 'Reproductive outcomes'</a>.)</p><p>Studies on UAE for adenomyosis show a 25 percent reduction in uterine volume and clinical improvement in abnormal bleeding and overall symptom reduction [<a href="#rid87">87-91</a>]. In a meta-analysis of observational studies including patients with adenomyosis undergoing uterine-sparing procedures, those undergoing UAE had recurrence and reintervention rates of 29.5 and 12.8 percent (16 studies); follow-up ranged from six months to seven years  (<a class="graphic graphic_table graphicRef142983" href="/z/d/graphic/142983.html" rel="external">table 4</a>) [<a href="#rid92">92</a>]. In one cohort study included in this meta-analysis, adverse outcomes occurring within 12 months of UAE included failed embolization (1.5 percent; 4 of 264 patients), premature ovarian insufficiency diagnosed within three months of the procedure (3 percent; 7 of 264), and there was one periprocedural death due to a pulmonary embolus [<a href="#rid93">93</a>]. From one to five years, an additional 57 patients were lost to follow-up, nine had hysterectomies, and three died of other causes. Among the 195 patients who completed five years of follow-up, approximately 70 percent of patients had improvement in painful and heavy menses and that improvement was greatest in patients with hypervascular lesions as determined by digital subtraction angiography at the time of treatment. </p><p class="headingAnchor" id="H3274509411"><span class="h3">Patients who desire future childbearing</span></p><p class="headingAnchor" id="H84584112"><span class="h4">Uterus-sparing resection</span><span class="headingEndMark"> — </span>Uterus-sparing resection of <strong>focal</strong> adenomyosis may be performed in patients who desire future childbearing and in whom first-line therapies were ineffective or contraindicated [<a href="#rid94">94-96</a>]. Unlike uterine leiomyomas, which can be readily shelled out from the surrounding myometrium, adenomyomas are not easily excised, a surgical plane often cannot be easily developed, and sharp dissection is required. Furthermore, the consistency of the adenomyotic uterus is described as "woody," and suturing is difficult in this environment. Surgical resection of <strong>diffuse</strong> adenomyosis is considered investigational [<a href="#rid97">97</a>]. Such surgical techniques include wedge resection of the uterine wall, transverse H-incision on the uterine fundus with resection of the adenomyosis, and Osada triple-flap method. </p><p>A preoperative MRI is obtained for such patients to evaluate the location and extent of the adenomyosis, determine if uterus-sparing surgery is feasible, and help the surgeon plan the procedure (see <a class="local">'Imaging'</a> above). Both laparoscopic and laparotomy techniques can be utilized.</p><p>The disadvantage of uterus-sparing resection is that even when performed by expert surgeons, the rate of uterine rupture in a future pregnancy is reported to be 4 percent and occurs between 12 and 35 weeks of gestation [<a href="#rid97">97</a>]. This rate exceeds the uterine rupture rate after myomectomy or classical cesarean birth (estimated risk of rupture with labor after classical cesarean: 2 percent [<a href="#rid98">98</a>]). Other pregnancy complications, such as abnormal placental attachment, have also been reported. </p><p>After uterine-sparing resection is performed, in vitro fertilization is often utilized to optimize the chance of conception prior to disease recurrence. If pregnancy needs to be delayed, hormonal agents (eg, GnRH agonists, the <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUD</a>) may be used to prevent recurrence and for symptom control [<a href="#rid99">99,100</a>]. (See <a class="local">'Alternative hormone strategies'</a> above and <a class="local">'52 mg levonorgestrel IUD'</a> above.)</p><p>During pregnancy, patients are managed even more conservatively than patients who have had other transmyometrial surgery and are candidates for prelabor cesarean birth. (See  <a class="medical medical_review" href="/z/d/html/4475.html" rel="external">"Cesarean birth: Preoperative planning and patient preparation", section on 'Scheduling'</a> and  <a class="medical medical_review" href="/z/d/html/4457.html" rel="external">"Repeat cesarean birth", section on 'Timing'</a>.)</p><p>Outcomes after uterine-sparing resection have been reported. In a meta-analysis of 12 studies including patients with adenomyosis undergoing uterus-sparing surgery, partial and complete excision of adenomyosis were associated with improvement of pain and menorrhagia and reduction in uterine volume [<a href="#rid101">101</a>]. Of the 364 patients who attempted to conceive, 35 percent were successful, and, of those, 18 percent miscarried, 7 percent delivered preterm, and 74 percent had a full-term birth. One uterine rupture occurred (1/126 or 0.8 percent). In the subsequent meta-analysis of observational studies discussed above (see <a class="local">'Uterine artery embolization, as an alternative'</a> above), those undergoing adenomyomectomy had recurrence and reintervention rates of 12.6 and 2.6 percent (14 studies); follow-up ranged from 13 months to seven years  (<a class="graphic graphic_table graphicRef142983" href="/z/d/graphic/142983.html" rel="external">table 4</a>) [<a href="#rid92">92</a>]. </p><p class="headingAnchor" id="H1628887227"><span class="h4">Other treatments</span><span class="headingEndMark"> — </span>Other uterine-sparing interventions, more commonly used for uterine fibroids, show some efficacy for treatment of adenomyosis. Case series of both ultrasound- or MRI-guided focused ultrasound surgery show both symptom improvement and uterine volume reduction with 6 to 12 months of follow-up [<a href="#rid102">102-105</a>]. Reports of laparoscopic radiofrequency ablation and transcervical radiofrequency ablation of uterine adenomyosis also suggest some efficacy in terms of short-term symptom improvement and volume reduction [<a href="#rid106">106,107</a>]. In the meta-analysis described above (see <a class="local">'Uterine artery embolization, as an alternative'</a> above), patients undergoing thermal ablation had recurrence and reintervention rates of 10 and 8.2 percent (12 studies); follow-up ranged from 12 months to five years  (<a class="graphic graphic_table graphicRef142983" href="/z/d/graphic/142983.html" rel="external">table 4</a>) [<a href="#rid92">92</a>]. (See  <a class="medical medical_review" href="/z/d/html/3316.html" rel="external">"Overview of endometrial ablation", section on 'Factors associated with treatment failure'</a>.)</p><p class="headingAnchor" id="H3596649118"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109362.html" rel="external">"Society guideline links: Abnormal uterine bleeding"</a>.)</p><p class="headingAnchor" id="H31291835"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87104.html" rel="external">"Patient education: Uterine adenomyosis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H10"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Uterine adenomyosis is a disorder in which endometrial glands and stroma are present within the myometrium (uterine musculature). The ectopic endometrial tissue appears to induce hypertrophy and hyperplasia of the surrounding myometrium, which results in a diffusely enlarged uterus (often termed "globular" enlargement). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The epidemiology of adenomyosis is uncertain because data regarding adenomyosis has often relied on the assessment of the uterus following hysterectomy. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical presentation</strong> – Common presenting symptoms of adenomyosis include heavy menstrual bleeding, painful menses, and chronic pelvic pain; patients may also be asymptomatic. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Associated conditions</strong> – Adenomyosis often coexists with other uterine diseases, particularly uterine leiomyomas and endometriosis, which can obscure the diagnosis of adenomyosis and make delineation of a symptom profile specific to adenomyosis difficult. (See <a class="local">'Associated conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation </strong>– Patients with suspected adenomyosis are evaluated with a medical history, pelvic examination, and pelvic imaging. There are no laboratory tests that diagnose adenomyosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Examination</strong> – On bimanual examination, the uterus is typically mobile, diffusely enlarged, soft (often referred to as "boggy"), and tender. (See <a class="local">'Pelvic examination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imaging</strong> – Transvaginal ultrasound is the first-line imaging choice for evaluation of an enlarged uterus, pelvic pain, and/or abnormal bleeding. Magnetic resonance imaging is typically reserved for patients in whom it is important to distinguish between diffuse and focal adenomyosis and/or to help with treatment planning. (See <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A definitive diagnosis of adenomyosis is made based on the finding of endometrial tissue within the myometrium during pathology evaluation of the uterus after hysterectomy  (<a class="graphic graphic_picture graphicRef141619" href="/z/d/graphic/141619.html" rel="external">picture 1</a>). A presumptive diagnosis of adenomyosis can be made in patients with characteristic clinical manifestations (eg, heavy menstrual bleeding, painful menses) in a patient with an enlarged uterus and imaging findings consistent with adenomyosis  (<a class="graphic graphic_figure graphicRef141558" href="/z/d/graphic/141558.html" rel="external">figure 2</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> <strong>of symptomatic patients</strong>  (<a class="graphic graphic_algorithm graphicRef141667" href="/z/d/graphic/141667.html" rel="external">algorithm 1</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>First-line therapies</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>NSAIDs</strong> – If not already initiated, nonsteroidal anti-inflammatory drugs (NSAIDs; <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>, <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a>, <a class="drug drug_general" data-topicid="9601" href="/z/d/drug information/9601.html" rel="external">mefenamic acid</a>) are often prescribed as a first line treatment as they are effective treatment options for heavy and painful menses, as discussed separately. (See <a class="local">'NSAIDs'</a> above and  <a class="medical medical_review" href="/z/d/html/5476.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Management", section on 'Nonhormonal therapies'</a> and  <a class="medical medical_review" href="/z/d/html/5414.html" rel="external">"Dysmenorrhea in adult females: Treatment", section on 'First-tier'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>LNG 52</strong> – For most patients with symptomatic adenomyosis, we also suggest treatment with the 52 mg levonorgestrel-releasing intrauterine device (LNG 52) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The LNG 52 provides direct action on the uterus, low systemic levels of steroid hormones, and long-acting user-independent administration. (See <a class="local">'First line therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternative hormone strategies</strong> – For patients who prefer not to, or cannot use, the LNG 52, other hormonal strategies (eg, oral contraceptive pills, gonadotropin-releasing hormone [GnRH] agonists and antagonists) may be used; data on efficacy are limited. (See <a class="local">'Alternative hormone strategies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Later-line therapies</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients who have completed childbearing</strong> –<strong> </strong>For patients who have completed childbearing and in whom first-line therapies were ineffective or contraindicated, we suggest hysterectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Hysterectomy is the definitive treatment option for adenomyosis. For patients who have failed hormonal treatment and decline, or have contraindications to hysterectomy, uterine artery embolization (UAE) may be used to reduce symptoms related to adenomyosis  (<a class="graphic graphic_diagnosticimage graphicRef53441" href="/z/d/graphic/53441.html" rel="external">image 4</a>). (See <a class="local">'Patients who have completed childbearing'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients who desire future childbearing</strong> – For Patients with <strong>focal</strong> adenomyosis who desire future childbearing and in whom first-line therapies were ineffective or contraindicated, uterus-sparing resection can be performed. Surgical resection of <strong>diffuse</strong> adenomyosis is considered investigational. Other uterine-sparing interventions (eg, ultrasound- or MRI-guided focused ultrasound surgery, laparoscopic or transcervical radiofrequency ablation) have been described. (See <a class="local">'Patients who desire future childbearing'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ferenczy A. Pathophysiology of adenomyosis. Hum Reprod Update 1998; 4:312.</a></li><li><a class="nounderline abstract_t">Mori T, Singtripop T, Kawashima S. Animal model of uterine adenomyosis: is prolactin a potent inducer of adenomyosis in mice? Am J Obstet Gynecol 1991; 165:232.</a></li><li><a class="nounderline abstract_t">Zou Y, Liu FY, Wang LQ, et al. Downregulation of DNA methyltransferase 3 alpha promotes cell proliferation and invasion of ectopic endometrial stromal cells in adenomyosis. Gene 2017; 604:41.</a></li><li><a class="nounderline abstract_t">Enatsu A, Harada T, Yoshida S, et al. Adenomyosis in a patient with the Rokitansky-Kuster-Hauser syndrome. Fertil Steril 2000; 73:862.</a></li><li><a class="nounderline abstract_t">Zhai J, Vannuccini S, Petraglia F, Giudice LC. Adenomyosis: Mechanisms and Pathogenesis. Semin Reprod Med 2020; 38:129.</a></li><li><a class="nounderline abstract_t">Brosens JJ, de Souza NM, Barker FG. Uterine junctional zone: function and disease. Lancet 1995; 346:558.</a></li><li><a class="nounderline abstract_t">Zhang Y, Yu P, Sun F, et al. Expression of oxytocin receptors in the uterine junctional zone in women with adenomyosis. Acta Obstet Gynecol Scand 2015; 94:412.</a></li><li><a class="nounderline abstract_t">Ibrahim MG, Chiantera V, Frangini S, et al. Ultramicro-trauma in the endometrial-myometrial junctional zone and pale cell migration in adenomyosis. Fertil Steril 2015; 104:1475.</a></li><li><a class="nounderline abstract_t">Wang S, Duan H, Zhang Y, Sun FQ. Abnormal Activation of RhoA/ROCK-I Signaling in Junctional Zone Smooth Muscle Cells of Patients With Adenomyosis. Reprod Sci 2016; 23:333.</a></li><li><a class="nounderline abstract_t">Upson K, Missmer SA. Epidemiology of Adenomyosis. Semin Reprod Med 2020; 38:89.</a></li><li><a class="nounderline abstract_t">Sztachelska M, Ponikwicka-Tyszko D, Martínez-Rodrigo L, et al. Functional Implications of Estrogen and Progesterone Receptors Expression in Adenomyosis, Potential Targets for Endocrinological Therapy. J Clin Med 2022; 11.</a></li><li><a class="nounderline abstract_t">Green AR, Styles JA, Parrott EL, et al. Neonatal tamoxifen treatment of mice leads to adenomyosis but not uterine cancer. Exp Toxicol Pathol 2005; 56:255.</a></li><li><a class="nounderline abstract_t">Ascher SM, Imaoka I, Lage JM. Tamoxifen-induced uterine abnormalities: the role of imaging. Radiology 2000; 214:29.</a></li><li><a class="nounderline abstract_t">Yamamoto T, Noguchi T, Tamura T, et al. Evidence for estrogen synthesis in adenomyotic tissues. Am J Obstet Gynecol 1993; 169:734.</a></li><li><a class="nounderline abstract_t">Ishihara H, Kitawaki J, Kado N, et al. Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas. Fertil Steril 2003; 79 Suppl 1:735.</a></li><li><a class="nounderline abstract_t">Nowak RA, Mora S, Diehl T, et al. Prolactin is an autocrine or paracrine growth factor for human myometrial and leiomyoma cells. Gynecol Obstet Invest 1999; 48:127.</a></li><li><a class="nounderline abstract_t">Stewart EA. Gonadotropins and the uterus: is there a gonad-independent pathway? J Soc Gynecol Investig 2001; 8:319.</a></li><li><a class="nounderline abstract_t">Danilovich N, Roy I, Sairam MR. Emergence of uterine pathology during accelerated biological aging in FSH receptor-haploinsufficient mice. Endocrinology 2002; 143:3618.</a></li><li><a class="nounderline abstract_t">Łupicka M, Socha BM, Szczepańska AA, Korzekwa AJ. Prolactin role in the bovine uterus during adenomyosis. Domest Anim Endocrinol 2017; 58:1.</a></li><li><a class="nounderline abstract_t">Mechsner S, Grum B, Gericke C, et al. Possible roles of oxytocin receptor and vasopressin-1α receptor in the pathomechanism of dysperistalsis and dysmenorrhea in patients with adenomyosis uteri. Fertil Steril 2010; 94:2541.</a></li><li><a class="nounderline abstract_t">Guo SW, Mao X, Ma Q, Liu X. Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis. Fertil Steril 2013; 99:231.</a></li><li><a class="nounderline abstract_t">Fiçicioğlu C, Tekin HI, Arioğlu PF, Okar I. A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats. Acta Eur Fertil 1995; 26:75.</a></li><li><a class="nounderline abstract_t">Maslar IA, Riddick DH. Prolactin production by human endometrium during the normal menstrual cycle. Am J Obstet Gynecol 1979; 135:751.</a></li><li><a class="nounderline abstract_t">Taran FA, Weaver AL, Coddington CC, Stewart EA. Understanding adenomyosis: a case control study. Fertil Steril 2010; 94:1223.</a></li><li><a class="nounderline abstract_t">Andersson JK, Khan Z, Weaver AL, et al. Vaginal bromocriptine improves pain, menstrual bleeding and quality of life in women with adenomyosis: A pilot study. Acta Obstet Gynecol Scand 2019; 98:1341.</a></li><li><a class="nounderline abstract_t">Ota H, Igarashi S, Sato N, et al. Distribution of tissue macrophages in uterine muscle layers in patients with adenomyosis. Med Sci Res 1991; 19:473.</a></li><li><a class="nounderline abstract_t">Matsumoto Y, Iwasaka T, Yamasaki F, Sugimori H. Apoptosis and Ki-67 expression in adenomyotic lesions and in the corresponding eutopic endometrium. Obstet Gynecol 1999; 94:71.</a></li><li><a class="nounderline abstract_t">Ota H, Igarashi S, Hatazawa J, Tanaka T. Immunohistochemical assessment of superoxide dismutase expression in the endometrium in endometriosis and adenomyosis. Fertil Steril 1999; 72:129.</a></li><li><a class="nounderline abstract_t">Propst AM, Quade BJ, Gargiulo AR, et al. Adenomyosis demonstrates increased expression of the basic fibroblast growth factor receptor/ligand system compared with autologous endometrium. Menopause 2001; 8:368.</a></li><li><a class="nounderline abstract_t">Propst AM, Quade BJ, Nowak RA, Stewart EA. Granulocyte macrophage colony-stimulating factor in adenomyosis and autologous endometrium. J Soc Gynecol Investig 2002; 9:93.</a></li><li><a class="nounderline abstract_t">Inoue S, Hirota Y, Ueno T, et al. Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Nat Commun 2019; 10:5785.</a></li><li><a class="nounderline abstract_t">Weiss G, Maseelall P, Schott LL, et al. Adenomyosis a variant, not a disease? Evidence from hysterectomized menopausal women in the Study of Women's Health Across the Nation (SWAN). Fertil Steril 2009; 91:201.</a></li><li><a class="nounderline abstract_t">Pinzauti S, Lazzeri L, Tosti C, et al. Transvaginal sonographic features of diffuse adenomyosis in 18-30-year-old nulligravid women without endometriosis: association with symptoms. Ultrasound Obstet Gynecol 2015; 46:730.</a></li><li><a class="nounderline abstract_t">Naftalin J, Hoo W, Nunes N, et al. Association between ultrasound features of adenomyosis and severity of menstrual pain. Ultrasound Obstet Gynecol 2016; 47:779.</a></li><li><a class="nounderline abstract_t">Naftalin J, Hoo W, Pateman K, et al. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. Hum Reprod 2012; 27:3432.</a></li><li><a class="nounderline abstract_t">McElin TW, Bird CC. Adenomyosis of the uterus. Obstet Gynecol Annu 1974; 3:425.</a></li><li><a class="nounderline abstract_t">Templeman C, Marshall SF, Ursin G, et al. Adenomyosis and endometriosis in the California Teachers Study. Fertil Steril 2008; 90:415.</a></li><li><a class="nounderline abstract_t">Molitor JJ. Adenomyosis: a clinical and pathological appraisal. Am J Obstet Gynecol 1971; 110:275.</a></li><li><a class="nounderline abstract_t">Panganamamula UR, Harmanli OH, Isik-Akbay EF, et al. Is prior uterine surgery a risk factor for adenomyosis? Obstet Gynecol 2004; 104:1034.</a></li><li><a class="nounderline abstract_t">Squillace ALA, Simonian DS, Allegro MC, et al. Adenomyosis and in vitro fertilization impacts - A literature review. JBRA Assist Reprod 2021; 25:303.</a></li><li><a class="nounderline abstract_t">Li X, Liu X, Guo SW. Clinical profiles of 710 premenopausal women with adenomyosis who underwent hysterectomy. J Obstet Gynaecol Res 2014; 40:485.</a></li><li><a class="nounderline abstract_t">Li C, Chen R, Jiang C, et al. Correlation of LOX‑5 and COX‑2 expression with inflammatory pathology and clinical features of adenomyosis. Mol Med Rep 2019; 19:727.</a></li><li><a class="nounderline abstract_t">Antero MF, Ayhan A, Segars J, Shih IM. Pathology and Pathogenesis of Adenomyosis. Semin Reprod Med 2020; 38:108.</a></li><li><a class="nounderline abstract_t">Ryan GL, Stolpen A, Van Voorhis BJ. An unusual cause of adolescent dysmenorrhea. Obstet Gynecol 2006; 108:1017.</a></li><li><a class="nounderline abstract_t">Parker JD, Leondires M, Sinaii N, et al. Persistence of dysmenorrhea and nonmenstrual pain after optimal endometriosis surgery may indicate adenomyosis. Fertil Steril 2006; 86:711.</a></li><li><a class="nounderline abstract_t">Kunz G, Beil D, Huppert P, et al. Adenomyosis in endometriosis--prevalence and impact on fertility. Evidence from magnetic resonance imaging. Hum Reprod 2005; 20:2309.</a></li><li><a class="nounderline abstract_t">Schindl M, Birner P, Obermair A, et al. Increased microvessel density in adenomyosis uteri. Fertil Steril 2001; 75:131.</a></li><li><a class="nounderline abstract_t">Kang S, Zhao J, Liu Q, et al. Vascular endothelial growth factor gene polymorphisms are associated with the risk of developing adenomyosis. Environ Mol Mutagen 2009; 50:361.</a></li><li><a class="nounderline abstract_t">Wang F, Li H, Yang Z, et al. Expression of interleukin-10 in patients with adenomyosis. Fertil Steril 2009; 91:1681.</a></li><li><a class="nounderline abstract_t">Yang JH, Wu MY, Chen MJ, et al. Increased matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 secretion but unaffected invasiveness of endometrial stromal cells in adenomyosis. Fertil Steril 2009; 91:2193.</a></li><li><a class="nounderline abstract_t">Chen N, Du B, Zhou H, et al. Abnormal expression of Nrf2 may play an important role in the pathogenesis and development of adenomyosis. PLoS One 2017; 12:e0182773.</a></li><li><a class="nounderline abstract_t">Zhou YF, Mori T, Kudo H, et al. Effects of angiogenesis inhibitor TNP-470 on the development of uterine adenomyosis in mice. Fertil Steril 2003; 80 Suppl 2:788.</a></li><li><a class="nounderline abstract_t">Juang CM, Chou P, Yen MS, et al. Adenomyosis and risk of preterm delivery. BJOG 2007; 114:165.</a></li><li><a class="nounderline abstract_t">Bruun MR, Arendt LH, Forman A, Ramlau-Hansen CH. Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small-for-gestational-age child: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018; 97:1073.</a></li><li><a class="nounderline abstract_t">Horton J, Sterrenburg M, Lane S, et al. Reproductive, obstetric, and perinatal outcomes of women with adenomyosis and endometriosis: a systematic review and meta-analysis. Hum Reprod Update 2019; 25:592.</a></li><li><a class="nounderline abstract_t">Maheshwari A, Gurunath S, Fatima F, Bhattacharya S. Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes. Hum Reprod Update 2012; 18:374.</a></li><li><a class="nounderline abstract_t">Tomassetti C, Meuleman C, Timmerman D, D'Hooghe T. Adenomyosis and subfertility: evidence of association and causation. Semin Reprod Med 2013; 31:101.</a></li><li><a class="nounderline abstract_t">Younes G, Tulandi T. Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis. Fertil Steril 2017; 108:483.</a></li><li><a class="nounderline abstract_t">Barrier BF, Malinowski MJ, Dick EJ Jr, et al. Adenomyosis in the baboon is associated with primary infertility. Fertil Steril 2004; 82 Suppl 3:1091.</a></li><li><a class="nounderline abstract_t">Bourdon M, Santulli P, Oliveira J, et al. Focal adenomyosis is associated with primary infertility. Fertil Steril 2020; 114:1271.</a></li><li><a class="nounderline abstract_t">Kok VC, Tsai HJ, Su CF, Lee CK. The Risks for Ovarian, Endometrial, Breast, Colorectal, and Other Cancers in Women With Newly Diagnosed Endometriosis or Adenomyosis: A Population-Based Study. Int J Gynecol Cancer 2015; 25:968.</a></li><li><a class="nounderline abstract_t">Yeh CC, Su FH, Tzeng CR, et al. Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study. PLoS One 2018; 13:e0194011.</a></li><li><a class="nounderline abstract_t">Levgur M. Diagnosis of adenomyosis: a review. J Reprod Med 2007; 52:177.</a></li><li><a class="nounderline abstract_t">Harmsen MJ, Van den Bosch T, de Leeuw RA, et al. Consensus on revised definitions of Morphological Uterus Sonographic Assessment (MUSA) features of adenomyosis: results of modified Delphi procedure. Ultrasound Obstet Gynecol 2022; 60:118.</a></li><li><a class="nounderline abstract_t">Byun JY, Kim SE, Choi BG, et al. Diffuse and focal adenomyosis: MR imaging findings. Radiographics 1999; 19 Spec No:S161.</a></li><li><a class="nounderline abstract_t">Liu L, Li W, Leonardi M, et al. Diagnostic Accuracy of Transvaginal Ultrasound and Magnetic Resonance Imaging for Adenomyosis: Systematic Review and Meta-Analysis and Review of Sonographic Diagnostic Criteria. J Ultrasound Med 2021; 40:2289.</a></li><li><a class="nounderline abstract_t">Katsumata Y, Noda M, Tanaka M, et al. [CT appearance of uterine adenomyosis]. Rinsho Hoshasen 1989; 34:227.</a></li><li><a class="nounderline abstract_t">Takeuchi H, Kitade M, Kikuchi I, et al. Diagnosis, laparoscopic management, and histopathologic findings of juvenile cystic adenomyoma: a review of nine cases. Fertil Steril 2010; 94:862.</a></li><li><a class="nounderline abstract_t">Troiano RN, Flynn SD, McCarthy S. Cystic adenomyosis of the uterus: MRI. J Magn Reson Imaging 1998; 8:1198.</a></li><li><a class="nounderline abstract_t">Tellum T, Matic GV, Dormagen JB, et al. Diagnosing adenomyosis with MRI: a prospective study revisiting the junctional zone thickness cutoff of 12 mm as a diagnostic marker. Eur Radiol 2019; 29:6971.</a></li><li><a class="nounderline abstract_t">Burghaus S, Drazic P, Wölfler M, et al. Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study. Int J Gynaecol Obstet 2024; 164:305.</a></li><li><a class="nounderline abstract_t">Chapron C, Vannuccini S, Santulli P, et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. Hum Reprod Update 2020; 26:392.</a></li><li><a class="nounderline abstract_t">Fong YF, Singh K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception 1999; 60:173.</a></li><li><a class="nounderline abstract_t">Fedele L, Bianchi S, Raffaelli R, et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997; 68:426.</a></li><li><a class="nounderline abstract_t">Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 2009; 79:189.</a></li><li><a class="nounderline abstract_t">Bragheto AM, Caserta N, Bahamondes L, Petta CA. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. Contraception 2007; 76:195.</a></li><li><a class="nounderline abstract_t">Shaaban OM, Ali MK, Sabra AM, Abd El Aal DE. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial. Contraception 2015; 92:301.</a></li><li><a class="nounderline abstract_t">Cope AG, Ainsworth AJ, Stewart EA. Current and Future Medical Therapies for Adenomyosis. Semin Reprod Med 2020; 38:151.</a></li><li><a class="nounderline abstract_t">Osuga Y, Fujimoto-Okabe H, Hagino A. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study. Fertil Steril 2017; 108:673.</a></li><li><a class="nounderline abstract_t">Osuga Y, Watanabe M, Hagino A. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis. J Obstet Gynaecol Res 2017; 43:1441.</a></li><li><a class="nounderline abstract_t">Huang FJ, Kung FT, Chang SY, Hsu TY. Effects of short-course buserelin therapy on adenomyosis. A report of two cases. J Reprod Med 1999; 44:741.</a></li><li><a class="nounderline abstract_t">Kitawaki J. Adenomyosis: the pathophysiology of an oestrogen-dependent disease. Best Pract Res Clin Obstet Gynaecol 2006; 20:493.</a></li><li><a class="nounderline abstract_t">Kavoussi SK, Esqueda AS, Jukes LM. Elagolix to medically treat a uterine adenomyoma: A case report. Eur J Obstet Gynecol Reprod Biol 2020; 247:266.</a></li><li><a class="nounderline abstract_t">Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med 2020; 382:328.</a></li><li><a class="nounderline abstract_t">Muneyyirci-Delale O, Archer DF, Owens CD, et al. Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis. F S Rep 2021; 2:338.</a></li><li><a class="nounderline abstract_t">Che X, Wang J, Sun W, et al. Effect of Mifepristone vs Placebo for Treatment of Adenomyosis With Pain Symptoms: A Randomized Clinical Trial. JAMA Netw Open 2023; 6:e2317860.</a></li><li><a class="nounderline abstract_t">Pelage JP, Jacob D, Fazel A, et al. Midterm results of uterine artery embolization for symptomatic adenomyosis: initial experience. Radiology 2005; 234:948.</a></li><li><a class="nounderline abstract_t">Nijenhuis RJ, Smeets AJ, Morpurgo M, et al. Uterine artery embolisation for symptomatic adenomyosis with polyzene F-coated hydrogel microspheres: three-year clinical follow-up using UFS-QoL questionnaire. Cardiovasc Intervent Radiol 2015; 38:65.</a></li><li><a class="nounderline abstract_t">de Bruijn AM, Smink M, Hehenkamp WJK, et al. Uterine Artery Embolization for Symptomatic Adenomyosis: 7-Year Clinical Follow-up Using UFS-Qol Questionnaire. Cardiovasc Intervent Radiol 2017; 40:1344.</a></li><li><a class="nounderline abstract_t">Kim MD, Kim S, Kim NK, et al. Long-term results of uterine artery embolization for symptomatic adenomyosis. AJR Am J Roentgenol 2007; 188:176.</a></li><li><a class="nounderline abstract_t">Kitamura Y, Allison SJ, Jha RC, et al. MRI of adenomyosis: changes with uterine artery embolization. AJR Am J Roentgenol 2006; 186:855.</a></li><li><a class="nounderline abstract_t">Liu L, Tian H, Lin D, et al. Risk of Recurrence and Reintervention After Uterine-Sparing Interventions for Symptomatic Adenomyosis: A Systematic Review and Meta-Analysis. Obstet Gynecol 2023; 141:711.</a></li><li><a class="nounderline abstract_t">Zhou J, He L, Liu P, et al. Outcomes in Adenomyosis Treated with Uterine Artery Embolization Are Associated with Lesion Vascularity: A Long-Term Follow-Up Study of 252 Cases. PLoS One 2016; 11:e0165610.</a></li><li><a class="nounderline abstract_t">Wood C. Surgical and medical treatment of adenomyosis. Hum Reprod Update 1998; 4:323.</a></li><li><a class="nounderline abstract_t">Kho KA, Chen JS, Halvorson LM. Diagnosis, Evaluation, and Treatment of Adenomyosis. JAMA 2021; 326:177.</a></li><li><a class="nounderline abstract_t">Kwack JY, Kwon YS. Laparoscopic Surgery for Focal Adenomyosis. JSLS 2017; 21.</a></li><li><a class="nounderline abstract_t">Osada H. Uterine adenomyosis and adenomyoma: the surgical approach. Fertil Steril 2018; 109:406.</a></li><li><a class="nounderline abstract_t">Landon MB, Hauth JC, Leveno KJ, et al. Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med 2004; 351:2581.</a></li><li><a class="nounderline abstract_t">Wu Q, Lian Y, Chen L, et al. Alleviation of Symptoms and Improvement of Endometrial Receptivity Following Laparoscopic Adenomyoma Excision and Secondary Therapy with the Levonorgestrel-releasing Intrauterine System. Reprod Sci 2020; 27:1259.</a></li><li><a class="nounderline abstract_t">Wang PH, Liu WM, Fuh JL, et al. Comparison of surgery alone and combined surgical-medical treatment in the management of symptomatic uterine adenomyoma. Fertil Steril 2009; 92:876.</a></li><li><a class="nounderline abstract_t">Mikos T, Lioupis M, Anthoulakis C, Grimbizis GF. The Outcome of Fertility-Sparing and Nonfertility-Sparing Surgery for the Treatment of Adenomyosis. A Systematic Review and Meta-analysis. J Minim Invasive Gynecol 2020; 27:309.</a></li><li><a class="nounderline abstract_t">Fukunishi H, Funaki K, Sawada K, et al. Early results of magnetic resonance-guided focused ultrasound surgery of adenomyosis: analysis of 20 cases. J Minim Invasive Gynecol 2008; 15:571.</a></li><li><a class="nounderline abstract_t">Zhou M, Chen JY, Tang LD, et al. Ultrasound-guided high-intensity focused ultrasound ablation for adenomyosis: the clinical experience of a single center. Fertil Steril 2011; 95:900.</a></li><li><a class="nounderline abstract_t">Zhang L, Rao F, Setzen R. High intensity focused ultrasound for the treatment of adenomyosis: selection criteria, efficacy, safety and fertility. Acta Obstet Gynecol Scand 2017; 96:707.</a></li><li><a class="nounderline abstract_t">Feng Y, Hu L, Chen W, et al. Safety of ultrasound-guided high-intensity focused ultrasound ablation for diffuse adenomyosis: A retrospective cohort study. Ultrason Sonochem 2017; 36:139.</a></li><li><a class="nounderline abstract_t">Hai N, Hou Q, Ding X, et al. Ultrasound-guided transcervical radiofrequency ablation for symptomatic uterine adenomyosis. Br J Radiol 2017; 90:20160119.</a></li><li><a class="nounderline abstract_t">Scarperi S, Pontrelli G, Campana C, et al. Laparoscopic Radiofrequency Thermal Ablation for Uterine Adenomyosis. JSLS 2015; 19.</a></li></ol></div><div id="topicVersionRevision">Topic 5489 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9825847" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pathophysiology of adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1853904" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Animal model of uterine adenomyosis: is prolactin a potent inducer of adenomyosis in mice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27986572" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Downregulation of DNA methyltransferase 3 alpha promotes cell proliferation and invasion of ectopic endometrial stromal cells in adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10731555" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Adenomyosis in a patient with the Rokitansky-Kuster-Hauser syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33032339" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Adenomyosis: Mechanisms and Pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7658784" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Uterine junctional zone: function and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25627343" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Expression of oxytocin receptors in the uterine junctional zone in women with adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26439760" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ultramicro-trauma in the endometrial-myometrial junctional zone and pale cell migration in adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26335177" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Abnormal Activation of RhoA/ROCK-I Signaling in Junctional Zone Smooth Muscle Cells of Patients With Adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33105509" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidemiology of Adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35956024" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Functional Implications of Estrogen and Progesterone Receptors Expression in Adenomyosis, Potential Targets for Endocrinological Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15816354" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Neonatal tamoxifen treatment of mice leads to adenomyosis but not uterine cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10644098" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Tamoxifen-induced uterine abnormalities: the role of imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8372890" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Evidence for estrogen synthesis in adenomyotic tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12620485" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10461005" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prolactin is an autocrine or paracrine growth factor for human myometrial and leiomyoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11750866" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gonadotropins and the uterus: is there a gonad-independent pathway?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12193578" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Emergence of uterine pathology during accelerated biological aging in FSH receptor-haploinsufficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27591979" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prolactin role in the bovine uterus during adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20413116" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Possible roles of oxytocin receptor and vasopressin-1αreceptor in the pathomechanism of dysperistalsis and dysmenorrhea in patients with adenomyosis uteri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22999795" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9098464" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/495675" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prolactin production by human endometrium during the normal menstrual cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19643403" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Understanding adenomyosis: a case control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31025313" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Vaginal bromocriptine improves pain, menstrual bleeding and quality of life in women with adenomyosis: A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Distribution of tissue macrophages in uterine muscle layers in patients with adenomyosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10389721" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Apoptosis and Ki-67 expression in adenomyotic lesions and in the corresponding eutopic endometrium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10428161" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Immunohistochemical assessment of superoxide dismutase expression in the endometrium in endometriosis and adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11528364" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Adenomyosis demonstrates increased expression of the basic fibroblast growth factor receptor/ligand system compared with autologous endometrium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11963838" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Granulocyte macrophage colony-stimulating factor in adenomyosis and autologous endometrium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31857578" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18243177" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Adenomyosis a variant, not a disease? Evidence from hysterectomized menopausal women in the Study of Women's Health Across the Nation (SWAN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25728241" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Transvaginal sonographic features of diffuse adenomyosis in 18-30-year-old nulligravid women without endometriosis: association with symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26499878" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Association between ultrasound features of adenomyosis and severity of menstrual pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23001775" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4608783" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Adenomyosis of the uterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919609" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Adenomyosis and endometriosis in the California Teachers Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5574629" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Adenomyosis: a clinical and pathological appraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15516398" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Is prior uterine surgery a risk factor for adenomyosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33656838" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Adenomyosis and in vitro fertilization impacts - A literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24148010" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical profiles of 710 premenopausal women with adenomyosis who underwent hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30387822" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Correlation of LOX‑5 and COX‑2 expression with inflammatory pathology and clinical features of adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33080632" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pathology and Pathogenesis of Adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17012466" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : An unusual cause of adolescent dysmenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16782099" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Persistence of dysmenorrhea and nonmenstrual pain after optimal endometriosis surgery may indicate adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15919780" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Adenomyosis in endometriosis--prevalence and impact on fertility. Evidence from magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11163827" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Increased microvessel density in adenomyosis uteri.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19197986" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Vascular endothelial growth factor gene polymorphisms are associated with the risk of developing adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18439592" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Expression of interleukin-10 in patients with adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18692810" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Increased matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 secretion but unaffected invasiveness of endometrial stromal cells in adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28817677" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Abnormal expression of Nrf2 may play an important role in the pathogenesis and development of adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14505755" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effects of angiogenesis inhibitor TNP-470 on the development of uterine adenomyosis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17169011" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Adenomyosis and risk of preterm delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29753309" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Endometriosis and adenomyosis are associated with increased risk of preterm delivery and a small-for-gestational-age child: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31318420" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Reproductive, obstetric, and perinatal outcomes of women with adenomyosis and endometriosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22442261" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23446857" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Adenomyosis and subfertility: evidence of association and causation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28865548" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15474079" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Adenomyosis in the baboon is associated with primary infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32868104" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Focal adenomyosis is associated with primary infertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25893280" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The Risks for Ovarian, Endometrial, Breast, Colorectal, and Other Cancers in Women With Newly Diagnosed Endometriosis or Adenomyosis: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29522577" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17465285" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Diagnosis of adenomyosis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34587658" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Consensus on revised definitions of Morphological Uterus Sonographic Assessment (MUSA) features of adenomyosis: results of modified Delphi procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10517452" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Diffuse and focal adenomyosis: MR imaging findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33502767" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Diagnostic Accuracy of Transvaginal Ultrasound and Magnetic Resonance Imaging for Adenomyosis: Systematic Review and Meta-Analysis and Review of Sonographic Diagnostic Criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2754818" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : [CT appearance of uterine adenomyosis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19539912" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Diagnosis, laparoscopic management, and histopathologic findings of juvenile cystic adenomyoma: a review of nine cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9848728" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cystic adenomyosis of the uterus: MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31264010" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Diagnosing adenomyosis with MRI: a prospective study revisiting the junctional zone thickness cutoff of 12 mm as a diagnostic marker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37635683" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32097456" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Diagnosing adenomyosis: an integrated clinical and imaging approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10640162" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9314908" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19185671" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17707716" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26071673" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33124017" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Current and Future Medical Therapies for Adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28911934" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28737239" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Long-term use of dienogest in the treatment of painful symptoms in adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10483548" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effects of short-course buserelin therapy on adenomyosis. A report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16564227" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Adenomyosis: the pathophysiology of an oestrogen-dependent disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32088070" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Elagolix to medically treat a uterine adenomyoma: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31971678" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34553161" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37307001" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effect of Mifepristone vs Placebo for Treatment of Adenomyosis With Pain Symptoms: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15681687" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Midterm results of uterine artery embolization for symptomatic adenomyosis: initial experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24692030" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Uterine artery embolisation for symptomatic adenomyosis with polyzene F-coated hydrogel microspheres: three-year clinical follow-up using UFS-QoL questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28516272" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Uterine Artery Embolization for Symptomatic Adenomyosis: 7-Year Clinical Follow-up Using UFS-Qol Questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17179361" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Long-term results of uterine artery embolization for symptomatic adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16498121" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : MRI of adenomyosis: changes with uterine artery embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36897132" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Risk of Recurrence and Reintervention After Uterine-Sparing Interventions for Symptomatic Adenomyosis: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27806072" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Outcomes in Adenomyosis Treated with Uterine Artery Embolization Are Associated with Lesion Vascularity: A Long-Term Follow-Up Study of 252 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9825848" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Surgical and medical treatment of adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34255015" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Diagnosis, Evaluation, and Treatment of Adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28642638" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Laparoscopic Surgery for Focal Adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29566853" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Uterine adenomyosis and adenomyoma: the surgical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15598960" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32046429" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Alleviation of Symptoms and Improvement of Endometrial Receptivity Following Laparoscopic Adenomyoma Excision and Secondary Therapy with the Levonorgestrel-releasing Intrauterine System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18774566" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Comparison of surgery alone and combined surgical-medical treatment in the management of symptomatic uterine adenomyoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31398415" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The Outcome of Fertility-Sparing and Nonfertility-Sparing Surgery for the Treatment of Adenomyosis. A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18657480" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Early results of magnetic resonance-guided focused ultrasound surgery of adenomyosis: analysis of 20 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21067723" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Ultrasound-guided high-intensity focused ultrasound ablation for adenomyosis: the clinical experience of a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28437003" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : High intensity focused ultrasound for the treatment of adenomyosis: selection criteria, efficacy, safety and fertility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28069193" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Safety of ultrasound-guided high-intensity focused ultrasound ablation for diffuse adenomyosis: A retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27792415" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Ultrasound-guided transcervical radiofrequency ablation for symptomatic uterine adenomyosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26648676" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Laparoscopic Radiofrequency Thermal Ablation for Uterine Adenomyosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
